ABSTRACT
INTRODUCTION
Hepatitis C virus (HCV), a globally expanding infective virus has already infected 123 million people worldwide [1] . Around 50-85% of the infected individuals develop chronic disease that may advance to cirrhosis and hepatocellular carcinoma [2] . Despite these alarming rates, no vaccine is available and the only established treatment [ribavirin + interferon (IFN)-is effective in less than 50% of the patients [3] . HCV has a singlestranded positive-sense RNA genome encoding three structural (core, E1, E2) and six nonstructural (NS) proteins [4] . Due to high mutation rates and generation of quasispecies, neutralizing antibodies targeted against envelope proteins, seem to be insufficient for HCV clearance. In contrast, vigorous and multi-specific CD8 + -cytotoxic T-lymphocyte (CTL)/T helper cell (Th)1 responses as well as high IFN-levels seem to play a significant role in acute self-limited HCV infection, while are weak or undetectable in chronic state [5;6] .
The potency of DNA vaccines to induce CTL responses [7] makes them promising candidates for protection against such viral infections. However, most HCV DNA vaccines failed to elicit protective responses due to the utilization of a complete antigen with limited numbers of dominant CTL epitopes, which are also faced with immune escape through antigenic variation [8] . Besides, presence of suppressive regions within the complete antigen may interfere with the function of dominant epitopes, as shown for structural and NS3 proteins of HCV, resulting in functional subversion of T cells, natural killer and dendritic cells [5;8;9] .
Identification of CD8 + CTL epitopes in HCV antigens has recently provided the opportunity for design of epitope-based immunogens by arranging isolated epitopes in a linear mosaicformat. The advantages of this multi-epitope (Polytope) approach include the co-delivery of multiple conserved and crucial epitopes from various antigens, and preventing deleterious effects encountered with the application of entire proteins [10;11] . Polytope vaccine studies were already described for different tumors and infectious diseases [11] and recently for HCV
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by application of epitopes derived from structural [9;12] and NS [12;13] proteins. However, general drawback of DNA vaccines is their limited potency and generation of low immune responses compared to classical vaccines [7] . This limitation is still more serious in case of recently considered as a promising approach for the efficient delivery of antigenic targets [17] [18] [19] . This so called "plasmo-VLP" strategy combines the ease of production of plasmid DNA and the improved immunogenicity of VLPs [17] .
Recently, we reported the engineering and construction of polytope DNA vaccine plasmids encoding four immunodominant CD8 + CTL epitopes derived from both structural and NS antigens of HCV and showed their eligibility by in vitro and primary in vivo analyses [20] .
In the present study, we provide a detailed and comparative immunological evaluation in BALB/c mice on induction of immune responses against two H-2 d -restricted epitopes incorporated into the same plasmids and further provide evidence that HBsAg fusion and DNA-prime/peptide-boost immunization conjoined to human compatible adjuvants enhance cellular responses and decrease the growth of transfected tumors in challenged mice.
MATERIALS AND METHODS

Polytope DNA constructs
In silico design and detailed construction procedure of polytope DNA vaccines exploited in this study, as well as their expression analyses through RT-PCR, dot-blot, Western-blot and immunofluorescence techniques was already described (20) . In brief, a polytope DNA respectively. The potency of particle formation for pcHPOL plasmid was also indirectly assessed through the measurement of HBsAg-based chimeric particles in the supernatant of transfected cells using a commercial HBsAg-ELISA assay (Hepanostika HBsAg Uni-Form II, Biomérieux, France) [20] .
Synthetic peptides
Peptides corresponding to CD8 + -epitopic peptides (C, E 4, E 6 , N) and an irrelevant H-2 drestricted epitope (core [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] ; NRRPQDVKFP), besides the synthetic CE 4 E 6 N long polytopic peptide were synthesized by solid phase Fmoc chemistry with 97% purity (Institute de Biochimie, Universite de Lausanne, Swiss). In this study, HLA-A2-restricted CD8 + -epitopic peptides (E 6 and N) were also used as irrelevant (negative control) peptides for all assays in BALB/c mice. (800 g/ml) for two months. The limiting diluted single clones were screened for the expression of CE 4 E 6 N gene through RT-PCR analysis (data not shown).
Establishment of CT26/CE
Mice and immunization protocols
Pathogen-free, female BALB/c (H-2 d ) mice (6-8 weeks old) were used and handled according to the international animal care ethics. Groups of six mice were immunized sub-cutaneously (s.c.) either in the hind footpad with 50 l of 2 mg/ml plasmids at weeks 0, 3 and 6, or in the tail base with 100 l of peptide immunogen containing 50 g of CE 4 E 6 N synthetic peptide + 50 g of CpG 1826 + 70% Montanide ISA 720 (M720) [25] , at days 0, 10 and 20.
Heterologous prime/boost immunization was performed using two DNA injections followed by one peptide administration at 3-week intervals (Table) .
Splenocyte isolation
Two weeks after the last injection, spleens of immunized mice were smashed into a cell homogenizer, washed with phosphate-buffered saline (PBS) and suspended in 0.83% NH 4 Cl solution for 5 min. to lyse the erythrocytes. After washing with PBS, spleen cells were suspended in complete RPMI-1640 medium, containing 10% fetal bovine serum (FBS), 2 mM L -glutamine, 100 mg/ml streptomycin and 100 U/ml penicillin, to provide single-cell suspension.
In vitro CTL assay
Single-cell splenocytes (2 × 10 6 cells/ml) were co-cultured with C and E 4 CD8 + -epitopicpeptides (10 g/ml of each) and incubated at 5% CO 2 , 37 °C for 4 days, when 10 U/ml of recombinant IL2 (Cedarlane, Canada) was added to the cultures. On the day 8, the CTLs were recovered by centrifugation, washed with PBS and employed as effector cells in a lactate dehydrogenase (LDH) release assay [25] . Briefly, within the wells of a round-bottom 96-well plate the effector cells were co-cultured with 6 × 10 3 peptide-pulsed P815 target cells at the effector/target ratios of 50:1, 25:1 and 12.5:1. After 6 h incubation at 5% CO 2 , 37 °C,
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supernatants were removed and measured for the release of LDH using Cytotox 96 kit (Promega, WI). The lysis percentage was calculated by the formula; Cytotoxicity (%) =
[(experimental lysis -spontaneous effector lysis -spontaneous target lysis) / (target maximum lysis -target spontaneous lysis)] 100. Spontaneous release was always < 5% of the maximum release (lysis with 1% Triton X-100) in all assays. To verify the responding cell type of CTL, blocking of cytotoxicity was carried out. To this end, rat anti-mouse CD4 (BD Pharmingen, Clone GK1.5) and rat anti-mouse CD8 (BD Pharmingen, Clone 53-6.7)
monoclonal antibodies were dropped into respective wells of CTL assay (10 g/ml).
Cytokine release assay
Single-cell splenocytes (2 × 10 6 cells/ml) were stimulated with CE 4 E 6 N synthetic peptide (10 M). After 72 h incubation at 5% CO 2 and 37 °C, supernatants were subjected to analysis of IL4 and IFN-levels by ELISA (U-CyTech, Netherlands).
Ex vivo Interferone--ELISpot assay
IFN--ELISpot kit (MabTech, Sweden) was used according to the manufacturer's instruction.
Briefly, in pre-coated wells 2 × 10 5 splenocytes were directly incubated with 10 U/ml of recombinant IL2 and 10 M of C, E 4 or irrelevant CD8 + -epitopic-peptides or CE 4 E 6 N synthetic peptide for 40 h at 5% CO 2 and 37 °C. After cell removal, washing steps and anti-IFN-antibody treatments, spot-forming cells (SFCs) were enumerated under a dissection stereoscope (Leica Microscopy system, Heerbrugg, Switzerland).
In vivo tumorigenicity assay
Three weeks after the last immunization, mice were injected s.c. in the right flank with 2 × 10 5 tumor cells (CT26/CE 4 E 6 N) in 100 l PBS. Tumor size was measured three times a week with a caliper and the volume was calculated using the formula; width × length × (width + length)/2. The pcHBs-primed/CE 4 E 6 N peptide-boosted control group was employed to investigate the role of pcHPOL in priming of T cells.
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Statistical analyses
All experiments were performed in triplicate and/or repeated three times. Prism-4 software was used for the data handling and statistical analyses were performed using Mann-Whitney nonparametric test and ANOVA. Statistical significance was set at p < 0.05.
RESULTS
Cellular responses in immunized mice
Results of CTL assay indicated a significant increase in specific lysis of C/E 4 peptide-pulsed P815 target cells by the splenocytes of polytope DNA-vaccinated groups (Table and Fig CD8 + -epitopic peptides (10-11 amino acid residues), as was consistently verified in our CTL blocking experiment using anti-CD4/CD8 antibodies. In fact, in silico analysis also predicted several CD4 + and B cell epitopes in CE 4 E 6 N polypeptide and accordingly antibodies were efficiently raised in rabbits immunized by this polypeptide confirming appearance of B-cell epitopes experimentally [20] . However, CE 4 E 6 N is an artificial sequence assembled from HCV CTL epitopes, which does not occur in natural HCV antigens, therefore, CD8 + -epitopespecific immunity and IFN-elicited through pulsing by C/E 4 peptides is the major point of interest in our study. Taken together, these results evidenced the proper processing of the CE 4 E 6 N construct towards the induction of the CD8 + -epitope-specific CTL responses against the incorporated murine epitopes (C and E 4 ) and enhancement of the responses by fusion of HBsAg.
Homologous versus heterologous immunization regimens
As shown in Fig. 3 , splenocytes of mice both primed and boosted with only CE 4 E 6 N peptide + CpG + M720 (i.e: no DNA priming) when stimulated with CE 4 E 6 N peptide in vitro, were efficient in both induction of IFN--producing cells (Table and Fig . 3B ) and secretion of IFN-/IL4 to the culture medium (Fig. 3C) . Nevertheless, the lowest number of C and E 4 -specific (Table and Fig . 3B, C) .
Interestingly, the heterologous DNA-prime/peptide-boosting approach induced a qualitatively broad Th1 response (IFN-/IL4 ratio ~3:1) as well as increased number of C/E 4 -specific SFCs (Table and Fig 
DISCUSSION
Multiepitope DNA vaccines may offer a promising approach towards the induction of safer and more effective immunity for highly variable pathogens like HCV, if their immune potencies are improved. Induction of CTL responses against HCV CTL epitopes of core [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] and E1 315-322 by a multiepitope DNA construct in the absence of an obvious source of CD4 + T cell help was recently shown [9] . However, the results of this prior study implied the need for pasteur-00744908, version 1 -24 Oct 2012 the enhancement of immunogenicity. We addressed this concern through well-defined in silico design and the development of an HBsAg-based plasmo-VLP polytope harboring multiple HCV-derived CTL epitopes in a DNA-prime/peptide-boosting approach. Although intramuscular route is generally used for DNA vaccination, however considering the fewer frequency of antigen presenting cells in muscle than skin [27] , we administrated polytope DNA plasmids subcutaneously in the footpad. Of note this route of immunization has been already shown to induce stronger Th1 and CTL responses than muscle [28] . We found that the fusion of HBsAg to the 5′ end of the polytope (in pcHPOL) effectively enhanced the activation of naïve CD8 + T cells and induced heightened CD8 + -epitope-specific T cell responses ( Fig. 2, 3A) . It should be noted that, the observed CTL responses in this study might correspond only to CD8 + T cells, because C and E 4 are CD8 + -epitopic peptides of 10-11 amino acid residues (that are not expected to elicit CD4 + T cells) and accordingly, CD4/CD8 blocking experiments also confirmed the correspondence of elicited CTL responses to CD8 + T cells. Besides, in vitro analysis of pcPOL and pcHPOL plasmids by normalized RT-PCR indicated the equal transcription levels for both constructs (data not shown), therefore, it is unlikely that the increased immune responses observed for pcHPOL were the consequence of increased expression. In contrast, these augmented responses may be most likely explained by secretion of HBsAg-based chimeric particles, which allows their efficient uptake and presentation not only to CD4 + but to CD8 + T cells by MHC-I molecules via a cross priming pathway [19] and leads to the induction of higher immune responses compared to intracellular or membrane-anchored proteins [29] . Of note, the partial secretion of HBsAg-based particles from Cos-7 cells transfected with pcHPOL plasmid was already reported [20] . However, besides the particle formation, characteristics such as the presence of multiple T helper epitopes and prolonged expression/secretion properties are other "helping" mechanisms involved in the immunocarrier effects of HBsAg [19;30] that may explain the augmented
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responses in this study. The inherent immunogenicity of HBsAg for better delivery of HCV [31;32] and other full-length antigens [18;30] was already described but to our knowledge this is the first report on such an application in a poly-CTL epitope immunogen.
Induction of higher T cell immunity by pcHPOL construct prompted us to asses the type and magnitude of the generated responses against the CE 4 E 6 N or C and E 4 epitopes in various prime/boost combinations of DNA (pcHPOL), peptide (CE 4 E 6 N) and DNA/peptide immunization regimens. As shown in Fig. 3B and 3C the mice primed and boosted with pcHPOL DNA alone (i.e: without any peptide boosting) developed relatively low T cell responses though it was epitope-specific and strongly Th1-biased. This low response despite the presence of HBsAg may be due to the low level antigen expression generally encountered with DNA vaccines [7] .
The group immunized only by adjuvant-formulated CE 4 E 6 N polypeptide demonstrated a strong and polytope-specific mixed Th1/Th2 response, but dramatically low against the incorporated CD8 + epitopes (C and E 4 ). This is consistent with previous observations for incompetence of peptide priming regimen towards the induction of CD8 + T cell responses [16] . Application of human-compatible adjuvant mixture of CpG/M720 in protein vaccination has been already shown to result in the induction of either more Th1-biased [33] or mixed Th1/Th2 [25] responses in mice, suggesting for the antigen-dependent role of these adjuvant on the quality of the induced responses. Although the balanced Th1/Th2 response may be generally appreciated as an advantage, however, since polytopes (like CE 4 E 6 N) are artificial sequences assembled from CTL epitopes, which are not present in natural (HCV) antigens, therefore Th1-biased epitope-specific CD8 + immunity is the only demanded response.
Accordingly, the pcHPOL-primed/CE 4 E 6 N peptide-boosted group promoted both the highest epitope-specific (CD8 + ) and Th1-type responses evidenced by IFN--ELISpot and cytokine secretion assays. Consistently, kinetic studies have also indicated the induction of higher pasteur-00744908, version 1 -24 Oct 2012 + T cell responses by priming and boosting that utilize alternate antigen presentation pathways [15] .
The most encouraging data obtained in our study was the partial regression of CE 4 E 6 Nexpressing tumor cells in the group immunized with pcHPOL plasmid and boosted with CE 4 E 6 N peptide (Fig. 4) . This inhibition of tumorigenicity was not observed in the case of pcPOL-injected mice, despite employing the DNA-prime/peptide-boosting regimen. The reason behind this observation may be the lack of CD4 + T cell help in construct containing only CD8 + CTL epitopes. This is in further agreement with recent claims for the inevitable requirement of CD8 + T cells to the help of CD4 + cells for efficient protection against HCV [5] . Our results in conjunction with similar observations [11;14] also propounded that the antigen used for CD4 stimulation needs not necessarily be of a cognate source related to the pathogen itself, as HBsAg was successfully employed for such a goal in case of HCV polytope construct in our study. In fact, bystander activation of T cells (e.g. epitope nonspecific T cell activation) either by cytokines acting independently of T cell receptor or by T cell receptor cross reactivity with HBsAg epitopes may be countered for augmenting immunogenicity [34] . Therefore, besides the particle formation and antigen presenting cell targeting by HBsAg, bystander activation of T cells may be another possible explanation for augmenting immunogenicity in case of pcHPOL. Hence, activated HBsAg-specific effector cell populations may influence the strength and quality of HCV epitope-specific cellular immune responses by cytokines. Accordingly, immunization with HBsAg plasmid DNA was previously shown to evoke Th1 cytokines probably due to the HBsAg-specific helper epitopes [19] . This observation is also consistent with the increased secretion of IFN-in pcHPOL immunized mice of our study compared to the group vaccinated with pcPOL plasmid, without any significant change in IL4 secretion (data not shown).
In summary, herein, we described a novel synthetic polytope arrangement based on four 
